These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16874013)

  • 21. Conventional dosing of anticancer agents: precisely wrong or just inaccurate?
    Bins S; Ratain MJ; Mathijssen RH
    Clin Pharmacol Ther; 2014 Apr; 95(4):361-4. PubMed ID: 24646486
    [No Abstract]   [Full Text] [Related]  

  • 22. The scientific basis of body surface area-based dosing.
    Chatelut E; Puisset F
    Clin Pharmacol Ther; 2014 Apr; 95(4):359-61. PubMed ID: 24646485
    [No Abstract]   [Full Text] [Related]  

  • 23. [Dose intensity in cancer chemotherapy (including high dose chemotherapy)].
    Ariyoshi Y; Ogawa M
    Gan To Kagaku Ryoho; 1994 Dec; 21(16):2699-707. PubMed ID: 7993104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Finding the right dose for cancer therapeutics--can we do better?
    Rubin EH; Anderson KM
    Clin Cancer Res; 2010 Feb; 16(4):1085-7. PubMed ID: 20145182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relevance of high-dose chemotherapy in solid tumours.
    Nieboer P; de Vries EG; Mulder NH; van der Graaf WT
    Cancer Treat Rev; 2005 May; 31(3):210-25. PubMed ID: 15944050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
    Schuchter LM
    J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
    [No Abstract]   [Full Text] [Related]  

  • 27. Chemotherapy-induced neutropenia: a useful predictor of treatment efficacy?
    Di Maio M; Gridelli C; Gallo C; Perrone F
    Nat Clin Pract Oncol; 2006 Mar; 3(3):114-5. PubMed ID: 16520781
    [No Abstract]   [Full Text] [Related]  

  • 28. [Dosage adjustment of antineoplastic agents in clinical practice].
    Milano G
    Bull Cancer; 1993 May; 80(5):374-5. PubMed ID: 8173190
    [No Abstract]   [Full Text] [Related]  

  • 29. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
    Zhao X; Xu X; Guo L; Ragaz J; Guo H; Wu J; Shao Z; Zhu J; Guo X; Chen J; Zhu B; Wang Z; Hu X
    Breast Cancer Res Treat; 2010 Dec; 124(3):733-43. PubMed ID: 20882405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dose intensity versus total dose of chemotherapy: an experimental basis.
    Skipper HE
    Important Adv Oncol; 1990; ():43-64. PubMed ID: 2182523
    [No Abstract]   [Full Text] [Related]  

  • 31. On metronomic chemotherapy: modulation of angiogenesis mediated by VEGE-A.
    Albertsson P; Lennernäs B; Norrby K
    Acta Oncol; 2006; 45(2):144-55. PubMed ID: 16546859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemotherapy dose and dose intensity: analyzing data to guide therapeutic decisions.
    Gillespie TW
    Oncol Nurs Forum; 2001 Mar; 28(2 Suppl):5-10. PubMed ID: 11291209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
    Shiraga E; Barichello JM; Ishida T; Kiwada H
    Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rationale for the use of alternating non-cross-resistant chemotherapy.
    Goldie JH; Coldman AJ; Gudauskas GA
    Cancer Treat Rep; 1982 Mar; 66(3):439-49. PubMed ID: 7060033
    [No Abstract]   [Full Text] [Related]  

  • 35. Phase I evaluation of IMPY in a twice weekly schedule.
    Haas CD; Joseph U; Belt RJ; Hoogstraten B
    Cancer Treat Rep; 1981; 65(5-6):439-41. PubMed ID: 7237464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Re: Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy?
    Block K; Koch A; Mead M; Newman RA; Gyllenhaal C
    J Natl Cancer Inst; 2009 Jan; 101(2):124-5; author reply 125-6. PubMed ID: 19141775
    [No Abstract]   [Full Text] [Related]  

  • 37. NCCN: High-dose chemotherapy. Applications of high-dose chemotherapy with bone marrow/stem cell support in solid tumors.
    Vaughan WP
    Cancer Control; 2001; 8(6 Suppl 2):50-2. PubMed ID: 11760558
    [No Abstract]   [Full Text] [Related]  

  • 38. Anticancer oral therapy: emerging related issues.
    Banna GL; Collovà E; Gebbia V; Lipari H; Giuffrida P; Cavallaro S; Condorelli R; Buscarino C; Tralongo P; Ferraù F
    Cancer Treat Rev; 2010 Dec; 36(8):595-605. PubMed ID: 20570443
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Will increases in chemotherapy dose intensity improve outcome of patients with common malignancies?
    Tannock I
    Am J Med; 1995 Dec; 99(6A):68S-69S. PubMed ID: 8585542
    [No Abstract]   [Full Text] [Related]  

  • 40. Multifractionated dosing for cancer chemotherapy: a novel schedule and a work in progress.
    Lokich J
    Cancer Invest; 1999; 17(7):551-4. PubMed ID: 10518201
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.